Topics and pooled relevance and evidence judgements of the TREC 2020 Precision Medicine track.
These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.
Release 2026-10-10-7b8f80935f90 · Evidence verified: Not verified
Exact outcomes, predictions, identifiers and evaluator are connected.
Missing or unresolved evidence
Verified: Not verified
Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.
Missing or unresolved evidence
Verified: Not verified
A pinned recipe describes the inputs, environment and resource requirements.
Missing or unresolved evidence
Verified: Not verified
Separate data and exposure records support an independent test.
Missing or unresolved evidence
Verified: Not verified
Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.
No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.
15 evaluations · 25 results. Different protocols are not a single leaderboard.
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: TREC 2020 PM run baseline (BIT.UA) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.532 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcebaseline (BIT.UA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 1: team 'BIT.UA', run 'baseline' |
| Configuration: TREC 2020 PM run baseline (BIT.UA) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.552 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcebaseline (BIT.UA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 2: team 'BIT.UA', run 'baseline' |
| Configuration: TREC 2020 PM run baseline (BIT.UA) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.421 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcebaseline (BIT.UA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 2: team 'BIT.UA', run 'baseline' |
| Configuration: TREC 2020 PM run bm25 (ASCFDA) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.535 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcebm25 (ASCFDA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 4: team 'ASCFDA', run 'bm25' |
| Configuration: TREC 2020 PM run CSIROmed_strRR (CSIROmed) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.53 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceCSIROmed_strRR (CSIROmed), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 2: team 'CSIROmed', run 'CSIROmed strRR' |
| Configuration: TREC 2020 PM run CSIROmed_strRR (CSIROmed) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.565 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceCSIROmed_strRR (CSIROmed), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 1: team 'CSIROmed', run 'CSIROmed strRR' |
| Configuration: TREC 2020 PM run CSIROmed_strRR (CSIROmed) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.436 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceCSIROmed_strRR (CSIROmed), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 1: team 'CSIROmed', run 'CSIROmed strRR' |
| Configuration: TREC 2020 PM run damoespcbh3 (ALIBABA) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.452 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcedamoespcbh3 (ALIBABA), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'exp-gains', row 1: team 'ALIBABA', run 'damoespcbh3' |
| Configuration: TREC 2020 PM run damoespcbh3 (ALIBABA) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.478 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcedamoespcbh3 (ALIBABA), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'std-gains', row 1: team 'ALIBABA', run 'damoespcbh3' |
| Configuration: TREC 2020 PM run duoT5 (h2oloo) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.512 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceduoT5 (h2oloo), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 4: team 'h2oloo', run 'duoT5' |
| Configuration: TREC 2020 PM run monoT5 (h2oloo) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.402 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcemonoT5 (h2oloo), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 5: team 'h2oloo', run 'monoT5' |
| Configuration: TREC 2020 PM run monoT5rct (h2oloo) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.419 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcemonoT5rct (h2oloo), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'exp-gains', row 2: team 'h2oloo', run 'monoT5rct' |
| Configuration: TREC 2020 PM run monoT5rct (h2oloo) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.424 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcemonoT5rct (h2oloo), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'std-gains', row 2: team 'h2oloo', run 'monoT5rct' |
| Configuration: TREC 2020 PM run pozbaseline (POZNAN) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.532 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcepozbaseline (POZNAN), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 5: team 'POZNAN', run 'pozbaseline' |
| Configuration: TREC 2020 PM run r1st (PINGAN NLP) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.418 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcer1st (PINGAN NLP), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 3: team 'PINGAN NLP', run 'r1st' |
| Configuration: TREC 2020 PM run rrf (BIT.UA) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.329 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcerrf (BIT.UA), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'exp-gains', row 4: team 'BIT.UA', run 'rrf' |
| Configuration: TREC 2020 PM run rrf_prf_rprec (ims unipd) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.316 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcerrf_prf_rprec (ims unipd), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'exp-gains', row 5: team 'ims unipd', run 'rrf prf rprec' |
| Configuration: TREC 2020 PM run rrf (BIT.UA) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.372 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcerrf (BIT.UA), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'std-gains', row 3: team 'BIT.UA', run 'rrf' |
| Configuration: TREC 2020 PM run sibtm_run1 (BITEM) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.528 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcesibtm_run1 (BITEM), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 3: team 'BITEM', run 'sibtm run1' |
| Configuration: TREC 2020 PM run sibtm_run1 (BITEM) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.402 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcesibtm_run1 (BITEM), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 4: team 'BITEM', run 'sibtm run1' |
| Configuration: TREC 2020 PM run uog_ufmg_sb_df5 (UoGTr) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.329 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceuog_ufmg_sb_df5 (UoGTr), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'exp-gains', row 3: team 'UoGTr', run 'uog ufmg sb df5' |
| Configuration: TREC 2020 PM run uog_ufmg_sb_df5 (UoGTr) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.498 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceuog_ufmg_sb_df5 (UoGTr), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 5: team 'UoGTr', run 'uog ufmg sb df5' |
| Configuration: TREC 2020 PM run uog_ufmg_sb_df5 (UoGTr) | Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.548 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceuog_ufmg_sb_df5 (UoGTr), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 3: team 'UoGTr', run 'uog ufmg bg df5' |
| Configuration: TREC 2020 PM run uog_ufmg_sb_df5 (UoGTr) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.368 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceuog_ufmg_sb_df5 (UoGTr), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'std-gains', row 4: team 'UoGTr', run 'uog ufmg sb df5' |
| Configuration: TREC 2020 PM run uwman (MRG UWaterloo) | Protocol: TREC 2020 PM Phase 2: evidence-tier-weighted ranking of retrieved abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot | 0.356 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourceuwman (MRG UWaterloo), TREC 2020 PM Phase 2 egfrnsclc-20261009-protocol-trec2020-pm-phase2-evidence Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 6 (PDF page 9), block 'std-gains', row 5: team 'MRG UWaterloo', run 'uwman' |
Source checking is not independent reproduction. Release 2026-10-10-7b8f80935f90.
A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
14 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| attributes.population 40 topics, each a cancer, a gene and a treatment; topics 15 and 16 are EGFR-mutant non-small cell lung cancer with afatinib and osimertinib. 22,806 Phase 1 relevance judgements and 2,691 Phase 2 evidence judgements; runs were scored on 31 topics (run appendix PDFs, not a source record of this batch). Context-only references | Overview of the TREC 2020 Precision Medicine Track Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Proceedings of the Twenty-Ninth Text REtrieval Conference (TREC 2020), NIST Special Publication 1266; 10-page PDF | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.population 40 topics, each a cancer, a gene and a treatment; topics 15 and 16 are EGFR-mutant non-small cell lung cancer with afatinib and osimertinib. 22,806 Phase 1 relevance judgements and 2,691 Phase 2 evidence judgements; runs were scored on 31 topics (run appendix PDFs, not a source record of this batch). Context-only references | TREC 2020 Precision Medicine topics Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: topics2020.xml as served on 2026-10-09 (40 topics) | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.scope_note Topics give no prior therapy, line of treatment or resistance context. Context-only references | Overview of the TREC 2020 Precision Medicine Track Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Proceedings of the Twenty-Ninth Text REtrieval Conference (TREC 2020), NIST Special Publication 1266; 10-page PDF | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.scope_note Topics give no prior therapy, line of treatment or resistance context. Context-only references | TREC 2020 Precision Medicine topics Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: topics2020.xml as served on 2026-10-09 (40 topics) | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.source_locator Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Context-only references | Overview of the TREC 2020 Precision Medicine Track Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Proceedings of the Twenty-Ninth Text REtrieval Conference (TREC 2020), NIST Special Publication 1266; 10-page PDF | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.source_locator Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Context-only references | TREC 2020 Precision Medicine topics Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: topics2020.xml as served on 2026-10-09 (40 topics) | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.total 40 Context-only references | Overview of the TREC 2020 Precision Medicine Track Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Proceedings of the Twenty-Ninth Text REtrieval Conference (TREC 2020), NIST Special Publication 1266; 10-page PDF | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.total 40 Context-only references | TREC 2020 Precision Medicine topics Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: topics2020.xml as served on 2026-10-09 (40 topics) | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.version TREC 2020 PM (MEDLINE baseline snapshot of the 2019 track) Context-only references | Overview of the TREC 2020 Precision Medicine Track Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Proceedings of the Twenty-Ninth Text REtrieval Conference (TREC 2020), NIST Special Publication 1266; 10-page PDF | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| attributes.version TREC 2020 PM (MEDLINE baseline snapshot of the 2019 track) Context-only references | TREC 2020 Precision Medicine topics Overview sections 3-6 and Table 3; topics2020.xml topics 15-16; run appendix PDFs list 31 topics Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: topics2020.xml as served on 2026-10-09 (40 topics) | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Release 2026-10-10-7b8f80935f90 · Record review: source checked
Stable ID: egfrnsclc-20261009-data-trec2020-pm-topics-medline